![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 4, 2410-2414, January 28, 2000
§,
From the
Department of Medicine, Wake Forest
University School of Medicine, Winston-Salem, North Carolina 27157 and the Departments of
Biological Chemistry and ¶ Radiation
Oncology, University of Michigan Medical School, Ann Arbor, Michigan
48109-0606
| |
ABSTRACT |
|---|
|
|
|---|
The yeast Cdc14 phosphatase has been shown to
play an important role in cell cycle regulation by dephosphorylating
proteins phosphorylated by the cyclin-dependent kinase
Cdc28/clb. We recently cloned two human orthologs of the yeast
CDC14, termed hCDC14A and -B, the gene products of which
share ~80% amino acid sequence identity within their N termini and
phosphatase domains. Here we report that the hCdc14A and hCdc14B
proteins interact with the tumor suppressor protein p53 both in
vitro and in vivo. This interaction is dependent on
the N termini of the hCdc14 proteins and the C terminus of p53.
Furthermore, the hCdc14 phosphatases were found to dephosphorylate p53
specifically at the p34Cdc2/clb phosphorylation site
(p53-phosphor-Ser315). Our findings that hCdc14 is a
cyclin-dependent kinase substrate phosphatase suggest that
it may play a role in cell cycle control in human cells. Furthermore,
the identification of p53 as a substrate for hCdc14 indicates that
hCdc14 may regulate the function of p53.
Cdc14 is a protein phosphatase conserved from yeast to man (1).
Genetic analyses suggest that the yeast Cdc14 plays pleiotropic roles
during the cell cycle, including the regulation of DNA replication and
the exit from mitosis (2, 3). Recent studies indicate that Cdc14 can,
in at least two ways, antagonize the cyclin-dependent kinase Cdc28/clb, which is the master regulator of the cell cycle in
yeast (5). Firstly, Cdc14 dephosphorylates the substrates phosphorylated by Cdc28/clb (4). Secondly, Cdc14 dephosphorylates the
transcription factor Swi5, resulting in the nuclear accumulation of
Swi5 and the transactivation of the Cdc28/clb inhibitor Sic1 (6). The
Cdc14 is itself regulated by compartmentalization in the nucleus.
During the G1, S, G2, and early mitosis Cdc14 is anchored in the nucleolus and redistributed throughout the nucleus
at the beginning of anaphase (7, 8).
Our laboratory has cloned two human orthologs of the yeast
CDC14, termed hCDC14A and hCDC14B, the gene products of
which share ~80% amino acid sequence identity within their N termini
and phosphatase domains (1). Both hCdc14A and hCdc14B were found to be
localized to the nucleus when overexpressed in mammalian cells. Using
the yeast strain harboring a temperature-sensitive mutation in the CDC14 gene, we showed that introduction of either of the two
human CDC14 genes could suppress the phenotype of the yeast
cdc14 temperature-sensitive mutant. This finding suggests
that the hCdc14s may perform functions in human cells similar to those
performed by the Cdc14 in yeast.
Analogous to the inactivation of the yeast Cdc28/clb by Swi5-induced
Sic1, the human p34Cdc2/clb kinase can in part be
inactivated by the p53-regulated Cdk inhibitor p21WAF1 (9).
Interestingly, p53 can be phosphorylated by human
p34Cdc2/clb at serine 315 (10), parallel to the fact that
Swi5 is phosphorylated by the yeast Cdc28/clb kinase (11). Because the
yeast Cdc14 can dephosphorylate Swi5, we wanted to explore whether the
hCdc14A and hCdc14B may dephosphorylate p53.
In this study, we report that the two hCdc14 phosphatases physically
interact with the p53 protein both in vitro and in
vivo. Such interaction involves the highly conserved N termini of
the hCdc14 proteins and the C terminus of p53. Furthermore, both hCdc14 forms could specifically dephosphorylate the p34Cdc2/clb
phosphorylation site of p53 (Ser315). We propose that
hCdc14 phosphatases may, together with p34Cdc2, regulate
p53 function by controlling the phosphorylation status of
Ser315 of p53.
Yeast Strains, Plasmids, and Recombinant Proteins--
The
Saccharomyces cerevisiae EGY48 strain was obtained from
CLONTECH and cultured according to the
manufacturer's suggested condition (CLONTECH). To
generate the pLexA-hCdc14B plasmid, the hCdc14B open reading frame
(ORF)1 was cloned in-frame
into the BamHI/XhoI restriction sites of the
pLexA vector (CLONTECH). The pLexA-PTP3 plasmid was
constructed by ligating the PCR product of the S. cerevisiae
phosphatase PTP3 ORF in-frame into the EcoRI/XhoI
restriction sites of the pLexA vector. The pB42AD-p53 plasmid was
constructed by ligating the PCR product of the human p53 ORF in-frame
into the EcoRI/XhoI restriction sites of the
pB42AD vector (CLONTECH). The construction of the
green fluorescent protein fusion plasmids pEGFP-hCdc14A, pEGFP-hCdc14As, and pEGFP-hCdc14B, as well as the plasmids pT7H-Cdc14A, pT7H-Cdc14B, pET-Cdc14A, and pET-Cdc14B were accomplished as described previously (1).
To make the pET-Cdc14A1-158 and
pET-Cdc14A120-580 plasmids, the hCdc14A coding sequences
from nucleotide 1 to 474 and 360 to 1740, respectively, were
PCR-amplified and ligated in-frame into the
NdeI/XhoI restriction sites of the pET23a vector (Novagen). The plasmids pET-Cdc14B1-230 and
pET-Cdc14B150-459 were constructed by PCR amplifying the
coding sequence of hCdc14B from nucleotide 1 to 690 and 450 to 1377, respectively, followed by ligation in-frame into the
NdeI/XhoI restriction sites of the pET23a vector.
The GST-p53 fusion plasmid pGST-p53 was constructed by cloning human
p53 ORF in-frame into the EcoRI/XhoI restriction
sites of the pGEX-5X-1 vector (Amersham Pharmacia Biotech). To make pGST-p531-210, pGST-p53100-296, and
pGST-p53250-393, the coding sequence of human p53 from
nucleotides 1 to 630, 300 to 788, and 750 to 1179, respectively, were
PCR-amplified and ligated in-frame into the
EcoRI/XhoI restriction sites of the pGEX-5X-1
vector. All constructs were sequenced using automated sequencing
(University of Michigan Sequencing Core Facility).
To synthesize 35S-labeled hCdc14 proteins, an in
vitro transcription/translation system from Promega was used.
Recombinant His6-tagged hCdc14 and GST-p53 proteins were
prepared from Escherichia coli as described previously (1,
12).
Two-hybrid Analysis--
The yeast strain EGY48 was transformed
with the bait plasmids pLexA, pLexA-hCdc14B, or pLexA-PTP3 as described
previously (1). Transformants carrying the bait plasmids were selected on SD In Vivo Expression of hCdc14 and Immunoprecipitation--
The
Epstein-Barr virus-transformed human cell line 293 was maintained in
Dulbecco's modified Eagle's medium with 10% fetal bovine serum and
10 units/ml penicillin/streptomycin. Cells were transfected with the
plasmids pEGFP-hCdc14A, pEGFP-hCdc14As, or pEGFP-hCdc14B using
LipofectAMINE according to the manufacturer's instructions (Life
Technologies, Inc.). 48 h after transfection, cells were lysed in
a phosphate-buffered saline buffer containing 1% Triton X-100, 50 mM NaCl, 1 mM dithiothreitol, proteinase
inhibitor mix (BMB). Endogenous p53 was immunoprecipitated using
polyclonal anti-p53 antibody (BMB). The immunoprecipitates were washed
with lysis buffer five times and subjected to SDS-PAGE analysis. The gel was blotted onto polyvinylidene difluoride membrane and probed with
anti-EGFP monoclonal antibody (CLONTECH) to analyze
whether any EGFP-hCdc14 fusion proteins may co-immunoprecipitate with p53.
In Vitro Binding Assay--
In vitro translated and
35S-labeled hCdc14 proteins were incubated with
glutathione-agarose-immobilized GST-p53 fusion proteins at 4 °C for
2 h in PBST (4 mM NaH2PO4, 16 mM Na2HPO4, 100 mM
NaCl, 0.5% Triton X-100, pH 7.4), 0.05% In Vitro Dephosphorylation of p53--
Purified recombinant
GST-p53 fusion proteins were phosphorylated in vitro by
either p34Cdc2/cyclin B kinase or CKII according to the
conditions provided by the manufacturer (New England Biolabs). The
phosphorylated GST-p53 fusion proteins (300 ng) in 50 µl of
glutathione-agarose beads were mixed with 1 µg of recombinant
hCdc14A, hCdc14B, PTEN, YG4E, or bovine serum albumin in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM dithiothreitol at 30 °C for 30 min. GST-p53
protein-agarose beads were then precipitated by centrifugation. The
relative amounts of 32P released into the supernatant as
well as the 32P bound to p53 were quantitated by
scintillation counting.
Human Cdc14 Proteins Interact with p53 in Vivo--
To study
whether the hCdc14 proteins could interact with the p53 protein, we
used the yeast two-hybrid assay. After co-transformation of
pLexA-hCdc14B and pB42AD-p53 plasmid into the S. cerevisiae EGY48 strain, the LEU reporter gene within the EGY48 strain
was activated and enabled the yeast cell to grow on selective media (see "Materials and Methods" for details). The colonies turned blue
as a result of lacZ gene activation (Fig.
1A). Yeast cells transformed
with either pLexA-hCdc14B or pB42AD-p53 alone could not grow on the
selective medium. Co-transformation with another unrelated phosphatase,
yeast PTP3 in the pLexA vector (pLexA-PTP3), along with pB42AD-p53 did
not result in the activation of the reporter gene (Fig. 1A).
These results indicate that the hCdc14B protein can physically interact
with p53.
To determine whether hCdc14A and hCdc14B interact with p53 in mammalian
cells, we performed co-immunoprecipitation experiments using extracts
from 293 cells transfected with either the EGFP-Cdc14A or EGFP-Cdc14B
fusion construct (pEGFP-Cdc14A and pEGFP-Cdc14B). Immunoprecipitation
of p53 was performed 48 h after transfection using anti-p53
antibodies. The immunoprecipitates were subjected to SDS-PAGE and
Western blot analysis with anti-EGFP antibodies. As shown in lane
1 of Fig. 1B, a band corresponding in size to the
EGFP-hCdc14A fusion protein (93 kDa) was detected on the blot, suggesting that EGFP-hCdc14A and p53 proteins co-existed in the immunocomplex. Lane 3 shows a band corresponding in size to
the EGFP-hCdc14B fusion protein (82 kDa), suggesting that the hCdc14B protein also formed immunocomplexes with the p53 protein.
Interestingly, p53 could also form immunocomplexes with EGFP-hCdc14As,
which lacks the C-terminal domain (truncated from amino acid 365). This result suggests that hCdc14s interact with p53 via their highly conserved N-terminal domain.
To ensure that the interaction between the hCdc14 phosphatases and p53
was specific and unique, the 293 cells were transfected with either the
EGFP vector alone or with another EGFP fusion construct coding for a
putative dual specific protein phosphatase PTEN (pEGFP-PTEN). In these
experiments, we could not detect any co-immunoprecipitation of either
PTEN or EGFP with the anti-p53 antibody (expected size of 75 and 27 kDa, respectively) (lanes 4 and 5). Western blot
with whole cell lysates indicated that all EGFP fusion proteins were
expressed at similar levels (data not shown). Taken together, the
results obtained with both the yeast two-hybrid system and with the
immunoprecipitation experiments demonstrated that the hCdc14A and
hCdc14B phosphatases can physically interact with p53.
The N terminus of hCdc14 Proteins and the C Terminus of p53 Are
Responsible for Their Interaction--
To further confirm that the N
terminus of hCdc14 interacts with p53, we performed binding assays
using full-length recombinant GST-p53 proteins and various truncation
mutants of hCdc14A and -B that had been synthesized by an in
vitro translation procedure. Both hCdc14A1-158 and
hCdc14B1-230 bound to GST-p53, whereas neither
hCdc14A120-580 nor hCdc14B150-459 did (Fig.
2, A and B). As a
control, we demonstrated that neither of these in vitro
translated hCdc14 proteins interacted with the GST protein (data not
shown).
We next performed in vitro binding assays to determine what
domain of the p53 protein is involved in the interaction.
35S-Labeled hCdc14A and hCdc14B proteins, synthesized from
pET-Cdc14A or pET-Cdc14B by in vitro translation, were
incubated with recombinant proteins of GST fused to various domains of
the p53 protein as indicated in Fig. 2C. As shown in Fig. 2,
D and E, the full-length GST-p53 protein as well
as the GST-p53250-393 bound well to hCdc14A and hCdc14B,
retaining ~20% of the input radiolabeled hCdc14s. In contrast,
except for the p53 N terminus (GST-p531-210), which bound
less than 2% of the input hCdc14B, GST-p531-210, GST-p53100-296, or GST could not bind tightly with hCdc14A or hCdc14B. Taken together, these results show that the N terminus of
Cdc14 and the C terminus of p53 are required for the interaction.
It has been shown that the C terminus of p53 undergoes phosphorylation
at multiple sites (reviewed in Ref. 13). p34Cdc2/clb kinase
can specifically phosphorylate p53 Ser315 in
vitro as well as in vivo (10, 14) whereas casein kinase II can specifically phosphorylate Ser392 of human p53 (15,
16). To examine whether the phosphorylation status of p53 can interfere
with its binding with hCdc14, GST-p53 proteins were specifically
labeled on Ser315 or Ser392 using
P34Cdc2/clb kinase or CKII kinase, respectively. We found
that GST-p53 with the Ser315 to Ala mutation abolished the
radioactive labeling by p34Cdc2/clb, suggesting the
specific labeling of the Ser315 site by
p34Cdc2/clb (data not shown). Ser315- or
Ser392-phosphorylated GST-p53 proteins bound equally well
as unphosphorylated GST-p53 to the in vitro translated
hCdc14A or hCdc14B protein (data not shown).
Human Cdc14 Protein Can Specifically Dephosphorylate
Ser315 of p53--
hCdc14 has been shown to act as a dual
specificity protein phosphatase (1). Because hCdc14A and hCdc14B were
found to physically interact with the C terminus of p53, we next
examined whether hCdc14 proteins dephosphorylate the C-terminal
phosphorylation site(s) of p53. Recombinant hCdc14A and hCdc14B with
C-terminal His6 tag were purified from E. coli
and incubated with GST-p53 phosphorylated at either Ser315
or Ser392. Both hCdc14A and hCdc14B were able to
dephosphorylate p53 phosphorylated at Ser315. About
30-50% of the total label incorporated at Ser315 was
removed by hCdc14A or hCdc14B within 30 min of incubation (Fig.
3). In contrast, neither hCdc14A nor
hCdc14B had any phosphatase activity toward p53 phosphorylated at
Ser392 (Fig. 3). As expected, the inactive mutant
(hCdc14BCS) protein with its catalytic cysteine mutated to serine does
not show any phosphatase activity against either site of p53. Two other
unrelated phosphatases (PTEN and YG4E proteins) were used in the assay
as controls. Like hCdc14, PTEN is a putative dual specific protein phosphatase with low activity against the artificial substrates p-nitrophenyl phosphate and 3-O-methylfluorescein
phosphate (1). YG4E is an active protein phosphatase that exhibits
strong activity against the substrates p-nitrophenyl
phosphate and 3-O-methylfluorescein phosphate (data not
shown). We found that neither PTEN nor YG4E could dephosphorylate
GST-p53 phosphorylated at Ser315 or Ser392
(Fig. 3).
The yeast Cdc14 protein phosphatase plays important roles in the
regulation of the cell cycle. As shown in the Fig.
4A, the yeast Cdc14
dephosphorylates several Cdc28/Clb substrates such as Hct1, Sic1, and
Swi5. Cdc14-mediated dephosphorylation of Hct1 results in degradation
of cyclin B (17), whereas dephosphorylation of the Cdc28/clb kinase
inhibitor Sic1 results in Cdc28/clb accumulation (18). Cdc14-mediated
dephosphorylation of the transcription factor Swi5 allows its nuclear
translocation and subsequent transactivation of Sic1 (19). Taken
together, the yeast Cdc14 appears to reverse the effects of Cdc28/clb
by directly dephosphorylating proteins phosphorylated by Cdc28/clb (4,
17).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Ura,
His plates. EGY48 cells carrying bait plasmids were then
transformed with the prey plasmids pB42AD or pB42AD-p53, and the
transformants were selected on SD
Ura,
His,
Trp plates. Any
interactions between the expressed protein products from the bait and
prey constructs result in the activation of the reporter genes
LEU and lacZ enabling the yeast cells to grow on
SD
Ura,
His,
Trp,
Leu (SD-UHWL) plates. X-gal was included in
the growth agar in order for the colonies expressing lacZ to turn blue.
-mercaptoethanol, 10%
glycerol, and 0.2 mM phenylmethylsulfonyl fluoride. After
washing the agarose beads six times with the above buffer, SDS sample
buffer was added, and the samples were boiled for 5 min and analyzed
using SDS-PAGE. The gel was treated with Amplify (Amersham Pharmacia
Biotech) and exposed to x-ray film.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (54K):
[in a new window]
Fig. 1.
Human Cdc14 proteins interact with p53.
A, two-hybrid analysis of the interaction between hCdc14B
and p53. Plasmids were transformed into S. cerevisiae EGY48
strain as described under "Materials and Methods." Transformants
carrying different combinations of plasmids were plated onto SD
Ura,
His,
Trp,
Leu, +X-gal plate. Only the strain carrying
pLexA-hCdc14B and pB42AD-p53 plasmids can grow and turn blue on such a
plate. B, co-immunoprecipitation of p53 and human GFP-Cdc14
fusion proteins. 293 cells were transfected with pEGFP-hCdc14A,
pEGFP-hCdc14As, pEGFP-hCdc14B, pEGFP-PTEN, or pEGFP-C2 (lanes
1-5) as described under "Materials and Methods." Following
immunoprecipitation with polyclonal anti-p53 antibody, the
immunoprecipitated proteins were analyzed on SDS-PAGE and blotted with
monoclonal anti-EGFP antibody. The expected positions of human
EGFP-hCdc14A, EGFP-hCdc14As, and EGFP-hCdc14B are marked.

View larger version (31K):
[in a new window]
Fig. 2.
The N terminus of hCdc14 proteins and the C
terminus of p53 are responsible for the interaction. A
and B, 5 µl each of the in vitro translated and
35S-labeled hCdc14A, hCdc14A1-158,
hCdc14A120-580 (A) or hCdc14B,
hCdc14B1-230, hCdc14B150-459 (B)
proteins were incubated with 50 µl (~300 ng) of agarose
bead-immobilized GST-p53 fusion protein as described under "Materials
and Methods." After washing, proteins stably bound to the agarose
beads were separated by SDS-PAGE, dried, and exposed to x-ray film.
Input, 1 µl of the 50-µl in vitro translation reaction.
C, SDS-PAGE of purified GST-p53 fusion proteins.
D and E, 5 µl each of the in vitro
translated and 35S-labeled hCdc14A (D) or B
(E) proteins were incubated with 50 µl (~300
ng) of agarose bead-immobilized GST or GST-p53 fusion proteins as
described under "Materials and Methods." After washing, proteins
stably bound to the agarose beads were separated by SDS-PAGE, dried,
and exposed to x-ray film. Input, 1 µl of the 50-µl in
vitro translation reaction.

View larger version (16K):
[in a new window]
Fig. 3.
Human Cdc14 can specifically dephosphorylate
the phosphor-Ser315 of p53. C-terminal
His6-tagged hCdc14 (A) and N-terminal
His6-tagged YG4E (B) and PTEN were expressed and
purified from E. coli. 1 µg each of the recombinant
proteins were incubated with 300 ng of agarose bead-bound
p53-[32P]Ser315 or
p53-[32P]Ser392 at 30 °C for 30 min as
described under "Materials and Methods." Free 32P was
separated from agarose bead-bound
p53-[32P]Ser315 or
p53-[32P]Ser392 by centrifugation and
subjected to scintillation counting. The ratio of free 32P
over total radioactivity was obtained.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (10K):
[in a new window]
Fig. 4.
The model of Cdc14 function in yeast and
man. A, a model showing yeast Cdc14 dephosphorylating
multiple substrates of Cdc28/clb and controlling mitotic exit.
B, a proposed model of hCdc14 dephosphorylating p53 and
counteracting p34Cdc2/clb activity.
We recently cloned the human Cdc14 orthologs, hCDC4A and hCdc14B (1). In this study, we found that hCdc14A and hCdc14B physically interact with the human tumor suppressor protein p53 both in vitro and in vivo. Such interaction specifically involves the highly conserved N termini of the hCdc14 proteins and the C terminus of the p53 protein. Furthermore, we showed that recombinant hCdc14A and hCdc14B specifically dephosphorylate p53 at Ser315, a site that has been shown to be phosphorylated by p34Cdc2/clb (10). No hCdc14 phosphatase activity was detected against p53 phosphorylated at the Ser392 site, which can be phosphorylated by casein kinase II (13). Other phosphatases tested, such as PTEN or YG4E, show no in vitro activity toward p53 phosphorylated at either Ser315 or Ser392. Our results that hCdc14s specifically dephosphorylate the p34Cdc2/clb phosphorylation site of p53 suggest that hCdc14 phosphatases may function analogously to the yeast Cdc14 by dephosphorylating substrate(s) of p34Cdc2/clb kinase.
p53 is a well studied tumor suppressor protein that plays important roles in the cellular response to DNA-damaging agents and other cellular stresses. p53 is normally present in low amounts in normal cells but accumulates in the cell nucleus in response to various cellular stresses (13). The nuclear accumulation of p53 leads to the transactivation of cyclin-dependent kinase inhibitor p21WAF1, causing cell cycle arrest at G1/S as well at the G2/M phase (20). In addition to their roles in G1 cell cycle arrest, p53 and p21WAF1 has been suggested to be involved in the regulation of the mitotic exit check point in mammalian cells (21). Loss or inactivation of p53 or p21WAF1 is associated with tetraploidy or aneuploidy due to the failure of cytokinesis (22-24). Furthermore, p53 appears to stimulate the exit of mitosis following a transient G2/M cell cycle arrest induced by various DNA-damaging agents in many cell types (25). Considering the fact that yeast Cdc14 facilitates mitotic exit by dephosphorylating Cdc28/clb substrates and in turn deactivating Cdc28/clb activity, we speculate that hCdc14-dependent dephosphorylation of p53 (and other p34Cdc2 substrates) may stimulate exit from mitosis in mammalian cells (Fig. 4B).
Human p53 has been shown to undergo numerous phosphorylations in vivo and in vitro. The phosphorylation status of p53 is determined by several kinases that target at least six different serines clustered in two domains on the protein (13). Two phosphorylated serines within the C terminus domain, Ser315 and Ser392, are phosphorylated by p34Cdc2/clb and casein kinase II, respectively (10, 15). p53 phosphorylation at Ser392 can enhance p53 sequence-specific DNA binding in vitro and is important for p53-mediated transcriptional activation in vivo (26). In addition, UV irradiation has been reported to increase the Ser392 phosphorylation (27, 28). Prolonged stability and/or activation of p53 by those phosphorylation events under stress conditions lead to G1/S or G2/M arrest. Several phosphatases including PP2A and PP5 have been inferred to inhibit p53 transcriptional activity by regulating the phosphorylation status of p53, although the targeting sites of these phosphatases are not known (29, 30). So far, the effect of Ser315 phosphorylation is not clear. Earlier studies showed that Ser315 phosphorylation increases the sequence-specific DNA binding capacity of p53, suggesting that Ser315 phosphorylation is an activating modification (10). However, mutation of the Ser315 residue has been reported to prolong the half-life of the p53 protein, suggesting that phosphorylation of Ser315 may target p53 for degradation (31). Contrary to those reports, recent studies in which Ser315 and other phosphorylation sites had been mutated suggest no role for the Ser315 in regulating the stability or activity of p53 (32, 33). Because the Ser315 site of p53 is located adjacent to its nuclear localization signal, it is conceivable that Ser315 phosphorylation may regulate p53 localization. Experiments studying the p53 localization showed that mutating Ser315 into alanine, which mimics constitutively dephosphorylated serine, does not affect the ability of p53 to translocate into the nucleus (34). However, it cannot be excluded from that study that phosphorylation of Ser315 may result in cytoplasmic retention of p53. In fact, the regulation of p53 nuclear export has been shown to be an important mechanism by which cells regulate p53 stability (35-37). Because the previous studies addressing p53 Ser315 phosphorylation were done using transient overexpression of p53 in transformed cell lines, they may fail to detect the effect of p53 Ser315 phosphorylation in normal cells, where only a minute amount of p53 is present. Further studies are needed to clarify the function of p53 Ser315 phosphorylation and its regulation by hCdc14 phosphatases.
In summary, our results demonstrate that hCdc14 proteins can interact
with p53 and specifically dephosphorylate the
p34Cdc2/clb-mediated Ser315 phosphorylation
in vitro. Such findings suggest that Cdc14 may be an
evolutionary conserved cyclin-dependent kinase phosphatase. Because the yeast Cdc14 phosphatase dephosphorylates multiple Cdc28/clb
substrates (3, 4), it is possible that one or both of the human Cdc14
proteins can dephosphorylate multiple substrates phosphorylated by Cdks
in mammalian cells. The fact that there are several closely related
human p53 homologues recently being discovered (p73 and
p63ket) raises an intriguing possibility that different
hCdc14 proteins might regulate different p53 homologues. Further study
regarding the regulation of hCdc14s will provide valuable insight
toward the understanding of mammalian cell cycle control and the
regulation of p53.
| |
FOOTNOTES |
|---|
* This work was supported by Cancer Biology Training Program National Institutes of Health Grant CA09676 (to L. L.) and by the Walther Cancer Institute (to J. E. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 336-716-6040; Fax: 336-716-3825; E-mail: lwli@wfubmc.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
ORF, open reading
frame;
PCR, polymerase chain reaction;
GST, glutathione
S-transferase;
X-gal, 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside;
PAGE, polyacrylamide gel electrophoresis;
GFP, green fluorescent
protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Li, L.,
Ernsting, B. R.,
Wishart, M. J.,
Lohse, D. L.,
and Dixon, J. E.
(1997)
J. Biol. Chem.
272,
29403-29406 |
| 2. | Hardy, C. F. (1996) Mol. Cell. Biol. 16, 1832-1841[Abstract] |
| 3. |
Jaspersen, S. L.,
Charles, J. F.,
Tinker-Kulberg, R. L.,
and Morgan, D. O.
(1998)
Mol. Biol. Cell
9,
2803-2817 |
| 4. | Visintin, R., Craig, K., Hwang, E. S., Prinz, S., Tyers, M., and Amon, A. (1998) Mol. Cell. 2, 709-718[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Mendenhall, M. D.,
and Hodge, A. E.
(1998)
Microbiol. Mol. Biol. Rev.
62,
1191-1243 |
| 6. | Toyn, J. H., Johnson, A. L., Donovan, J. D., Toone, W. M., and Johnston, L. H. (1997) Genetics 145, 85-96[Abstract] |
| 7. | Visintin, R., Hwang, E. S., and Amon, A. (1999) Nature 398, 818-823[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Shou, W., Seol, J. H., Shevchenko, A., Baskerville, C., Moazed, D., Chen, Z. W., Jang, J., Shevchenko, A., Charbonneau, H., and Deshaies, R. J. (1999) Cell 97, 233-244[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Dulic, V., Kaufman, W. K., Wilson, S. J., Tlsty, T. D., Lee, E., Harper, J. W., Elledge, S. J., and Reed, S. I. (1994) Cell 76, 1013-1023[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Wang, Y., and Prives, C. (1995) Nature 376, 88-91[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Moll, T., Tebb, G., Surana, U., Robitsch, H., and Nasmyth, K. (1991) Cell 66, 743-758[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Gottlin, E. B.,
Xu, X.,
Epstein, D. M.,
Burke, S. P.,
Eckstein, J. W.,
Ballou, D. P.,
and Dixon, J. E.
(1996)
J. Biol. Chem.
271,
27445-27449 |
| 13. |
Ko, L. J.,
and Prives, C.
(1996)
Genes Dev.
10,
1054-1072 |
| 14. |
Bischoff, J. R.,
Friedman, P. N.,
Marshak, D. R.,
Prives, C.,
and Beach, D.
(1990)
Proc. Natl. Acad. Sci. U.S.A.
87,
4766-4770 |
| 15. | Meek, D. W., Simon, S., Kikkawa, U., and Eckhart, W. (1990) EMBO J. 9, 3253-3260[Medline] [Order article via Infotrieve] |
| 16. | Herrmann, C. P., Kraiss, S., and Montenarh, M. (1991) Oncogene 6, 877-884[Medline] [Order article via Infotrieve] |
| 17. | Jaspersen, S. L., Charles, J. F., and Morgan, D. O. (1999) Curr. Biol. 9, 227-236[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Verma, R., Feldman, R. M., and Deshaies, R. J. (1997) Mol. Biol. Cell 8, 1427-1437[Abstract] |
| 19. |
Jans, D. A.,
Moll, T.,
Nasmyth, K.,
and Jans, P.
(1995)
J. Biol. Chem.
270,
17064-17067 |
| 20. | O'Connor, P. M. (1997) Cancer Surv. 29, 151-182[Medline] [Order article via Infotrieve] |
| 21. |
Cross, S. M.,
Sanchez, C. A.,
Morgan, C. A.,
Schimke, M. K.,
Ramel, S.,
Idzerda, R. L.,
Raskind, W. H.,
and Reid, B. J.
(1995)
Science
267,
1353-1356 |
| 22. | Chang, T. H., Ray, F. A., Thompson, D. A., and Schlegel, R. (1997) Oncogene 14, 2383-2393[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Bunz, F.,
Dutriaux, A.,
Lengauer, C.,
Waldman, T.,
Zhou, S.,
Brown, J. P.,
Sedivy, J. M.,
Kinzler, K. W.,
and Vogelstein, B.
(1998)
Science
282,
1497-1500 |
| 24. | Barboule, N., Chadebech, P., Baldin, V., Vidal, S., and Valette, A. (1997) Oncogene 15, 2867-2875[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Guiilouf, C., Roselli, F., Kirshnaraju, K., Moustacchi, E., Hoffman, B., and Lieberman, D. A. (1995) Oncogene 10, 2263-2270[Medline] [Order article via Infotrieve] |
| 26. |
Hupp, T. R.,
Meek, D. W.,
Midgley, C. A.,
and Lane, D. P.
(1993)
Nucleic Acids Res.
21,
3167-3174 |
| 27. |
Kapoor, M.,
and Loranzo, G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2834-2837 |
| 28. |
Lu, H.,
Taya, Y.,
Ikeda, M.,
and Levine, A. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6399-6402 |
| 29. | Yan, Y., Shay, J. W., Wright, W. E., and Mumby, M. C. (1997) J. Biol. Chem. 273, 15220-15226 |
| 30. | Zuo, Z., Dean, N. M., and Honkanen, R. E. (1998) J. Biol. Chem. 272, 12250-12258 |
| 31. |
Lin, W. C.,
and Desiderio, S.
(1993)
Science
260,
953-959 |
| 32. |
Ashcroft, M.,
Kubbutat, M. H.,
and Vousden, K. H.
(1999)
Mol. Cell. Biol.
19,
1751-1758 |
| 33. | Hengstermann, A., Whitaker, N. J., Zimmer, D., Zentgraf, H., and Scheffner, M. (1998) Oncogene 17, 2933-2941[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Liang, S. H.,
Hong, D.,
and Clarke, M. F.
(1998)
J. Biol. Chem.
273,
19817-19821 |
| 35. | Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. F. (1999) EMBO J. 18, 1660-1672[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Freedman, D. A.,
and Levine, A. J.
(1998)
Mol. Cell. Biol.
18,
7288-7293 |
| 37. | Lain, S., Midgley, C., Sparks, A., Lane, E. B., and Land, D. P. (1999) Exp. Cell. Res. 248, 457-472[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
J. Wu, H. P. Cho, D. B. Rhee, D. K. Johnson, J. Dunlap, Y. Liu, and Y. Wang Cdc14B depletion leads to centriole amplification, and its overexpression prevents unscheduled centriole duplication J. Cell Biol., May 1, 2008; 181(3): 475 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yuan, H. Hu, Z. Guo, G. Fu, A. P. Shaw, R. Hu, and X. Yao Phospho-regulation of HsCdc14A By Polo-like Kinase 1 Is Essential for Mitotic Progression J. Biol. Chem., September 14, 2007; 282(37): 27414 - 27423. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. North and E. Verdin Mitotic Regulation of SIRT2 by Cyclin-dependent Kinase 1-dependent Phosphorylation J. Biol. Chem., July 6, 2007; 282(27): 19546 - 19555. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Chung and C. Eng Nuclear-Cytoplasmic Partitioning of Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Differentially Regulates the Cell Cycle and Apoptosis Cancer Res., September 15, 2005; 65(18): 8096 - 8100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Vazquez-Novelle, V. Esteban, A. Bueno, and M. P. Sacristan Functional Homology among Human and Fission Yeast Cdc14 Phosphatases J. Biol. Chem., August 12, 2005; 280(32): 29144 - 29150. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Q. Wang, J. Bembenek, K. R. Gee, H. Yu, H. Charbonneau, and Z.-Y. Zhang Kinetic and Mechanistic Studies of a Cell Cycle Protein Phosphatase Cdc14 J. Biol. Chem., July 16, 2004; 279(29): 30459 - 30468. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Dryden, F. A. Nahhas, J. E. Nowak, A.-S. Goustin, and M. A. Tainsky Role for Human SIRT2 NAD-Dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle Mol. Cell. Biol., May 1, 2003; 23(9): 3173 - 3185. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Gruneberg, M. Glotzer, A. Gartner, and E. A. Nigg The CeCDC-14 phosphatase is required for cytokinesis in the Caenorhabditis elegans embryo J. Cell Biol., September 3, 2002; 158(5): 901 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Kaiser, Z. A. Zimmerman, H. Charbonneau, and P. K. Jackson Disruption of Centrosome Structure, Chromosome Segregation, and Cytokinesis by Misexpression of Human Cdc14A Phosphatase Mol. Biol. Cell, July 1, 2002; 13(7): 2289 - 2300. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Alarcon-Vargas and Z.'e. Ronai p53-Mdm2--the affair that never ends Carcinogenesis, April 1, 2002; 23(4): 541 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ljungman and M. T. Paulsen The Cyclin-Dependent Kinase Inhibitor Roscovitine Inhibits RNA Synthesis and Triggers Nuclear Accumulation of p53 That Is Unmodified at Ser15 and Lys382 Mol. Pharmacol., October 1, 2001; 60(4): 785 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu and M. Kulesz-Martin p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding Carcinogenesis, June 1, 2001; 22(6): 851 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Klibanov, H. O'Hagan, and M Ljungman Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress J. Cell Sci., January 5, 2001; 114(10): 1867 - 1873. [Abstract] [PDF] |
||||
![]() |
J. P. Blaydes, M. G. Luciani, S. Pospisilova, H. M.-L. Ball, B. Vojtesek, and T. R. Hupp Stoichiometric Phosphorylation of Human p53 at Ser315 Stimulates p53-dependent Transcription J. Biol. Chem., February 9, 2001; 276(7): 4699 - 4708. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Traverso, C. Baskerville, Y. Liu, W. Shou, P. James, R. J. Deshaies, and H. Charbonneau Characterization of the Net1 Cell Cycle-dependent Regulator of the Cdc14 Phosphatase from Budding Yeast J. Biol. Chem., June 8, 2001; 276(24): 21924 - 21931. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||